On January 4, 2024, Allogene Therapeutics Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products, and Foresight Diagnostics, the leader in the development of ultra-sensitive liquid biopsy circulating tumor DNA (ctDNA) detection, announced a strategic partnership to develop a minimal residual disease (MRD) in-vitro diagnostic (IVD) to determine eligibility in ALPHA3, the first pivotal trial for first line (1L) consolidation treatment of large B-cell lymphoma (LBCL). Wilson Sonsini Goodrich & Rosati advised Foresight Diagnostics on the transaction.

The ALPHA3 trial uses Foresight’s investigational PhasED-Seq™ ctDNA-MRD platform to identify patients with MRD after 1L treatment for LBCL. The study will evaluate whether such patients benefit from consolidation with cemacabtagene ansegedleucel, or cema-cel (previously known as ALLO-501A). If successful, cema-cel could become part of the 1L treatment plan for newly diagnosed LBCL patients who are at a high risk for recurrence. Start-up activities for the ALPHA3 trial have been initiated.

The Wilson Sonsini team that advised Foresight on the transaction included Ian Edvalson, Zack Burns, Maya Skubatch, and Kassandra Castillo.

For more information, please see the companies’ news release.